Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?-Reference-Cited by-同舟云学术

Response to: Are we confident treating pT1a G1 lymphovascular space invasion-negative patients (with myometrial invasion) with chemoradiotherapy on the basis of p53abn?

Published:2021-04-28 Issue: Volume: Page:ijgc-2021-002668
ISSN:1048-891X
Container-title:International Journal of Gynecologic Cancer
language:en
Short-container-title:Int J Gynecol Cancer

Author:

Concin Nicole^ORCID,Matias-Guiu Xavier,Creutzberg Carien L

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Reference4 articles.

1. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma

2. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer—Combined Analysis of the PORTEC Cohorts

3. Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series

4. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy;León-Castillo;J Clin Oncol,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer;International Journal of Gynecologic Cancer;2024-05-30

2. Update in the molecular classification of endometrial carcinoma;International Journal of Gynecologic Cancer;2023-03

3. Integration of Molecular Data in the Prognostic Stratification and Management of Endometrial Carcinoma;Journal of Personalized Medicine;2022-12-18